Interstitial brachytherapy combined with parp inhibitors in the treatment of chemoresistant recurrent epithelial ovarian cancer: a case report

HIGHLIGHTS

• who: Yuan Bian and collaborators from the Kore University of Enna, Italy have published the research: Interstitial brachytherapy combined with PARP inhibitors in the treatment of chemoresistant recurrent epithelial ovarian cancer: A case report, in the Journal: (JOURNAL)
• what: For these patients, however, the overall objective response rate (ORR) is modest (u226420%), the PFS is limited (median 3-4 months), and the life expectancy is short ( and amp;lt;12 months) .
• how: This result is significantly greater than several previous results(median PFS of 2.9 months) with single-agent olaparib therapy in . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.